Annals of Oncology Submission Guide: Requirements & What Editors Want

How this page was created: we reviewed the current Elsevier guide for authors, Annals of Oncology journal information, ESMO positioning, recent accepted-article patterns, and Manusights pre-submission review notes for oncology manuscripts.

We reviewed the 100 most recent Annals of Oncology papers used when this guide was built, including DOI spot-checks such as 10.1016/j.annonc.2026.02.014, 10.1016/j.annonc.2026.01.009, and 10.1016/j.annonc.2025.12.023. We compared those accepted-paper patterns with recent manuscripts that were looking to submit to this journal through our Manusights work reviews.

Manusights internal analysis identifies a failure pattern: weak Annals of Oncology submissions often contain publishable oncology data, but the title, abstract, endpoint maturity, biomarker validation, and first table do not make the clinical-priority case before editorial triage.

Evidence boundary: Elsevier provides the official article-type and formatting requirements, but it cannot tell authors whether a trial, biomarker, real-world evidence, or translational oncology package is high-priority enough for Annals of Oncology. The useful submission decision is whether the manuscript would still look broadly oncology-relevant without the cover letter explaining why.

Before a credible Annals of Oncology submission enters the system, the package should already make four things easy to see:

• what oncology problem is being changed or clarified

• why the result matters beyond one narrow tumor-specific readership

• why the evidence is strong enough for a high-priority editorial read

• why the translational or clinical meaning is already mature, not still forming

At a minimum, that usually means:

• a title and abstract that expose the oncology consequence quickly

• first figures or tables that support the main treatment or interpretation case

• reporting, ethics, trial, and disclosure materials that already look stable

• a manuscript that is legible to oncologists outside the exact niche

• a cover letter that argues journal fit and priority, not only prestige

• a key message that can explain the paper in 400 characters without hype

The most common failures here are package-shape failures, not upload failures.

• The paper is still niche-first. Editors can tell when the broad-oncology case is being forced.

• The significance claim outruns the evidence. High-priority journals punish overstatement fast.

• The translational layer is present but not clinically consequential. Biological interest alone does not complete the case.

• The first read is too slow. If the importance is buried under setup, editorial momentum drops.

• The compliance package feels underbuilt. Weak ethics, reporting, or disclosure materials make the manuscript feel less mature.

• Manuscript specifications:

• Original articles should generally be no longer than 4,500 words, excluding manuscript heading, abstract, acknowledgements, funding, and references

• Tables and figures are not strictly capped, but no more than 6 total is recommended

• The abstract should be structured and 300 words or fewer

• Authors should provide a maximum of 6 keywords

• Original articles and reviews need a 400-character key message for the online table of contents

• Required documents:

• Cover letter stating the report is not under consideration elsewhere and all named authors agreed to submission

• Ethics committee approval statement where appropriate

• Funding statement and disclosure statement

• Any registered clinical trial number after the abstract

• Supplementary files uploaded separately if used

• Manuscript file in Word format if possible; the archive instructions explicitly say xls/ppt/latex/pdf are not acceptable manuscript formats

• Clinical trial specific requirements:

The archived author guide is unusually explicit about what gets priority:

• randomized clinical trials are evaluated against CONSORT and may go to statistical review

• phase I reports need an additional translational component unless the response signal is truly exceptional

• phase II studies should test novel ideas and produce data that either support important randomized trials or clearly argue against them

• single-arm phase II combination studies with established drugs but no additional translational research cannot be considered

• single-biomarker studies with no real future clinical utility cannot be considered

That is a stronger readiness test than generic "high-impact oncology journal" advice. The paper has to look useful for real oncology decisions, not just interesting.

• Technical formatting:

• The archived instructions point authors to the online submission site rather than email handling

• Word documents are strongly recommended for the manuscript

• Figures should be uploaded separately, typically as TIFF/JPEG or EPS

• Tables should be editable and uploaded separately

• If you are planning open-access publication or print-colour charges, verify the live journal site before submission because those commercial details can change

Use the journal's live submission portal linked from the author site. The archived instructions route authors to direct online submission and say original articles should generally be submitted directly for a rapid response rather than relying on presubmission queries.

The current Elsevier guide points authors to Editorial Manager for Annals of Oncology at Editorial Manager submission portal. Use that portal for the author profile, presubmission-enquiry workflow where relevant, and manuscript upload. The practical interpretation is simple: do not prepare an email submission package, and do not treat the ESMO society page as the intake path. The journal is an Elsevier/ESMO title, but the upload decision happens through the Editorial Manager record.

The authors' controllable risk is not the portal sequence. It is whether the priority case is visible before the editorial screen reaches the supplement.

Day 0: Editorial Manager upload

The file enters the Annals of Oncology record with title, abstract, article type, declarations, manuscript file, tables, figures, supplement, and key-message materials.

Days 1 to 3: technical and editorial-office checks

The office can catch missing ethics statements, trial-registration details, disclosure fields, file-format issues, or incomplete reporting materials before priority triage.

Week 1: clinical-priority screen begins

Editors start judging whether the title, abstract, first table or figure, and journal-fit note show particular significance in clinical oncology.

Weeks 2 to 3: lower-priority return window

If the paper is solid but not high-priority enough for Annals of Oncology, this is the window where the archived instructions say returns happen whenever possible.

• Day 0: submit through Editorial Manager with title, abstract, article type, declarations, and files.

• Days 1-3: technical checks catch missing ethics, disclosure, trial-registration, key-message, or file-format details.

• Week 1: editors begin clinical-priority and article-type screening.

• Weeks 2-3: lower-priority papers are returned whenever possible.

• Weeks 3-6: stronger files move through reviewer, statistical, or editorial decision preparation.

• Step 1: Manuscript type selection

Choose the article type honestly. In the archived instructions the main active lanes are original articles, reviews, and letters. Case reports are not considered unless they are framed as a letter responding to previously published work.

• Step 2: Author information entry

List corresponding author first, then all co-authors in publication order. Include ORCID identifiers where available and add institutional affiliations exactly as they should appear in publication.

• Step 3: Manuscript details

Enter the title exactly as written in the manuscript and make sure the abstract can carry the paper by itself. The archived guide requires a structured abstract of 300 words or fewer and no more than 6 keywords.

• Step 4: File uploads

Upload the manuscript in Word if possible, because the archived guide strongly recommends Word and says xls/ppt/latex/pdf are not acceptable manuscript formats. Upload figures and tables separately in editable or journal-approved formats, and keep any supplementary files clearly labeled.

• Step 5: Submission checklist

The system generates an automated checklist. Common missing items: line numbers, page numbers, reference formatting, figure legends, table titles.

• Technical troubleshooting:

The main practical risk here is not browser trivia. It is uploading a package that is technically complete but still makes the editor work too hard to understand the priority claim. Keep filenames simple, keep the figure package clean, and make the key message readable without the supplement.

Before submitting to Annals of Oncology, an Annals of Oncology submission readiness check identifies whether the package meets the editorial bar before you commit to the submission.

Your cover letter needs three jobs: explain the oncology consequence, explain why the evidence package is mature enough for this journal, and explain why the paper belongs in Annals of Oncology rather than a narrower oncology title.

• Paragraph 1: Clinical impact statement

Open with the oncology problem and the practical consequence. State clearly what the manuscript changes for treatment, interpretation, or patient selection.

• Paragraph 2: Study design justification

Explain why the evidence is mature enough now. This is where you frame trial design, endpoint quality, validation depth, translational support, or why a negative result still gives clear guidance for future work.

• Paragraph 3: Why this journal

Explain why the paper belongs in a broad oncology conversation instead of a narrower disease-specific title. That is often the hidden decision the editor is making first.

• Template structure:

"Dear Editors, [oncology problem and the practical change your paper makes]. [why the evidence package is mature and decision-relevant now]. [why the manuscript deserves broad oncology readership rather than only a specialist audience]."

Don't mention journal impact factor or readership size. The editors know their own journal's influence.

• Broad-journal language wrapped around a narrow oncology story. Editors can spot when the audience claim is being forced.

• A translational layer with no real clinical consequence. Interesting biology is not the same as a strong Annals of Oncology package.

• Phase I or phase II work that is still too preliminary for a high-priority screen. The archived guide is explicit that early-phase work needs translational strength or unusually strong response signal.

• Single-biomarker logic with weak future clinical utility. The author guide explicitly warns against this class of paper.

• A weak first-page package. If the title, abstract, and first figures do not establish why the paper matters, the rest of the file often never gets a fair chance.

Source: Annals of Oncology general instructions for authors, Oxford Academic archive

The archived instructions say the editorial office aims to return papers of insufficient priority within 3 weeks whenever possible, and that authors will normally be notified of acceptance, rejection, or need for revision within 6 weeks of submission.

That should be treated as directional rather than guaranteed, but it is more useful than relying on folklore-level review-time estimates.

• What those numbers really mean:

• a fast return often means the editor judged the paper as insufficient priority for this journal, not that the study was unsound

• surviving past the first few weeks usually means the paper is still being compared, assigned, or routed for review

• the 6-week notification line is a directional target, not a promise that every file will resolve on that clock

• Practical expectation:

Use the 3-week and 6-week signals to judge whether the paper is in the early priority screen or the deeper review path, but do not build your submission strategy around folklore-level exact status timing.

Before you upload, run your manuscript through an Annals of Oncology submission readiness check to catch the issues editors filter for on first read.

Across oncology manuscripts targeting Annals of Oncology, three recurring decision risks matter most across submissions that the journal's editors filter out at the desk-screen stage.

Relevant published-guidance constraints:

• ESMO published guidelines, Annals of Oncology publishes clinical and translational oncology with explicit direct-clinical-relevance-to-oncology-practice requirement

• Original Articles no more than 3,000 words body + 250-word structured abstract + 6 figures/tables combined + Vancouver references + reporting-guideline compliance for clinical studies

ESMO editors are particularly alert to single-arm Phase II trials framed as evidence for changing standard of care. The journal publishes Phase III randomized data and high-quality Phase II work with appropriate comparators.

Mechanistic studies entirely in cell lines or animal models without a clear translational bridge to clinical practice are rejected for scope. Novel tumor-biology findings without clinical implications at treatment-selection, biomarker-use, or patient-stratification level are also weak fits. Use the three checks below before you open the Annals of Oncology Editorial Manager upload slot.

This guide tells you what Annals of Oncology editors look for before reviewer assignment, and Manusights checks whether your paper passes the clinical-priority, trial-maturity, biomarker-utility, first-table/figure, reporting-checklist, ethics/trial-registration, and cover-letter tests that official Elsevier and ESMO guidance cannot evaluate from a generic checklist. Paid Manusights reviews are covered by a 60-day money-back guarantee, and we never train on submitted manuscripts.

Clinical priority is not visible in the title and abstract

Across Annals of Oncology-targeted manuscripts, we consistently see authors submit work where the clinical-priority case is present in the cover letter but not established by the title and abstract independently. ESMO editors triage on clinical significance from the title and abstract alone within 3 weeks; manuscripts that require the cover letter to make the clinical-significance argument fail the triage screen.

Specific patterns editors flag at desk:

• title and abstract describe methodology / cohort / statistical analysis without naming the clinical decision the work informs

• abstract Conclusions section states "implications for clinical practice" without naming the specific oncology decision (treatment-selection / sequencing / dosing / biomarker-use / patient-stratification / monitoring / supportive-care / risk-prediction)

• abstract emphasizes statistical significance (p-values, hazard ratios) without translating to clinically meaningful magnitudes, such as NNT / NNH, median PFS or OS differences with confidence intervals, biomarker AUC with NPV/PPV, or risk-stratification cutoffs with clinical-decision implications

• abstract uses generic oncology terms ("cancer patients," "treatment outcomes," "survival") rather than disease-specific terms (named tumor type with stage and biomarker status, named treatment with named comparator, named patient population with eligibility criteria)

• cover letter explains clinical priority but title and abstract do not

• lower-priority papers (single-arm Phase II, retrospective single-institution series, biomarker discovery without validation) framed in title and abstract as if they were Phase III evidence

Manuscripts where clinical priority is not visible in title and abstract face desk rejection within the 3-week window with redirect to:

• ESMO Open (ESMO open-access companion accepting broader scope including some single-arm Phase II / Phase I work with translational component)

• Cancer Cell (Cell Press cancer flagship)

• Nature Medicine (broader Nature-portfolio for paradigm-changing clinical-translational)

• Cancer Discovery (AACR translational with stronger biology focus)

• Clinical Cancer Research (AACR clinical-translational)

• Journal of Clinical Oncology (ASCO for US-anchored clinical oncology)

• Lancet Oncology (Lancet flagship with broader policy framing)

• JAMA Oncology (JAMA Network for US-anchored practice-changing clinical)

• JNCI (NCI flagship)

• British Journal of Cancer

• specialty disease-site journals, such as Blood for hematologic oncology, JTO for thoracic oncology, European Urology for GU oncology, Annals of Surgery for surgical oncology, Breast Cancer Research and Treatment for breast cancer, and Gut for GI oncology

The fix is to write the title and abstract so the clinical decision is named explicitly: title leads with the disease + intervention + clinical-decision impact; abstract Conclusions names the specific clinical-practice change with effect-size in clinically-meaningful units (NNT / NNH / median PFS-OS differences with CIs / biomarker AUC with NPV-PPV / risk-stratification cutoff); abstract uses disease-and-treatment-specific terms throughout; cover letter complements rather than carries the clinical-priority case.

Check whether your Annals of Oncology abstract shows clinical priority →

Early-phase trial data lacks a definitive bridge

We frequently see Annals of Oncology manuscripts submit Phase I trial data without the translational component the editorial guidelines require for Phase I work, or Phase II data without the novel-hypothesis-testing or randomized-comparator design the journal expects for Phase II.

ESMO editors are particularly alert to single-arm Phase II trials framed as evidence for changing standard of care: the journal's editorial culture prefers Phase III randomized data, and Phase II submissions require either randomized-comparator design or appropriate single-arm design with prospective primary-endpoint matching reported result and explicit clinical-decision framing.

Specific patterns editors flag:

• Phase I dose-escalation / safety study without translational biomarker component (named PK / PD / receptor occupancy / target engagement / immunological biomarker / molecular response with quantitative readout)

• Phase I expansion-cohort data without molecular-correlate analysis (named biomarker-stratified response with mechanism)

• Phase II single-arm efficacy with response rate or PFS framed as practice-changing without acknowledging single-arm limitations and named historical-control or external-control comparison

• Phase II without prospective primary-endpoint matching report (post-hoc primary endpoint chosen after seeing data)

• Phase II without appropriate sample-size justification (Simon two-stage design / O'Brien-Fleming / matched-pair design / adaptive design with prospective specification)

• early-phase data without explicit demonstration of how the results support or argue against a definitive randomized trial (named Phase III trial design that the early-phase data informs)

• Phase I/II combined-modality study without each modality-component contribution dissected (combination effect attributed to one component without ablation)

• biomarker-defined Phase II expansion without genuine biomarker-targeted hypothesis (post-hoc subgroup analysis dressed as biomarker-defined cohort)

• registration-enabling Phase II without FDA / EMA accelerated-approval pathway alignment named

Manuscripts with Phase I or Phase II data lacking translational support or definitive-trial bridge face desk rejection or major revision with redirect to: ESMO Open (broader ESMO OA accepting Phase I/II with translational component); Clinical Cancer Research (AACR Phase I/II with translational); Cancer Discovery (Phase I/II with strong biology); Journal of Clinical Oncology (ASCO Phase II with appropriate design); JCO Precision Oncology (precision-oncology Phase I/II); Investigational New Drugs (Springer Phase I/II focus); Cancer Chemotherapy and Pharmacology (PK/PD-focused); BJC; Oncologist.

The fix is to structure Phase I submissions around translational component (named biomarker / PK-PD / target-engagement readout connecting drug exposure to molecular and clinical effect); structure Phase II submissions as either randomized-comparator design (named comparator + appropriate randomization + intention-to-treat analysis) or appropriately-designed single-arm (named historical / external control + Simon two-stage design + prospective primary endpoint + acknowledged single-arm limitations);

demonstrate explicit Phase III bridge (named definitive trial that the early-phase data informs or argues against, with explicit go-no-go criteria); and either invest in the appropriate trial design from the start or route honestly to ESMO Open / sibling venue.

Check whether your Annals of Oncology early-phase trial package has a definitive bridge →

Single-biomarker claims lack clinical utility

The third recurring pattern in Annals of Oncology-targeted manuscripts is single-biomarker discovery studies reporting statistically-significant associations between a biomarker and a clinical outcome without demonstrating actionable future clinical utility. The Annals of Oncology author guide explicitly states that single-biomarker studies with no real future clinical utility cannot be considered.

ESMO editors specifically check whether the biomarker study:

• identifies the clinical decision the biomarker informs (treatment selection between named alternatives, patient stratification for named clinical pathway, prognosis with named risk-stratification cutoff, monitoring with named treatment-modification rule, early-detection with named screening protocol, prediction of named adverse event with named monitoring frequency, prediction of treatment response with named treatment-modification rule)

• validates the biomarker beyond discovery (named discovery + named validation cohorts with appropriate population matching, ideally prospective validation

• named training-test cohort separation

• named analytical validation per CAP-CLIA / IVDR / FDA-approved-test pathway

• named clinical-utility study demonstrating biomarker-driven decision changes outcome compared to biomarker-blind decision)

• reports performance with clinically-meaningful metrics (sensitivity / specificity / NPV / PPV / AUC with confidence intervals

• effect modification on treatment effect with quantitative magnitude

• net reclassification improvement with appropriate baseline)

• demonstrates practical implementation feasibility (named assay platform with turnaround time, named cost considerations, named availability in routine clinical practice or path to availability, named training requirements)

• addresses regulatory and reimbursement context (FDA / EMA companion-diagnostic pathway alignment if relevant, named clinical-guideline body the biomarker informs, named reimbursement consideration)

• engages with current biomarker-research literature explicitly (REMARK reporting compliance, named existing biomarkers in the same indication with comparative performance)

Single-biomarker studies lacking demonstrated clinical utility get desk-rejected with redirect to: ESMO Open (broader scope including biomarker-discovery), Cancer Biomarkers (specialty biomarker journal); Molecular Cancer Therapeutics (mechanism-and-biomarker focus); JCO Precision Oncology (precision-oncology biomarker-focused); Annals of Surgical Oncology (when surgical biomarker); JAMA Oncology (when clinical-decision-changing biomarker); Cancer Discovery (when strong biology); specialty disease-site journals.

The fix is to either invest in the clinical-utility evidence (validation cohort + clinical-utility study + analytical validation + implementation feasibility + regulatory context + REMARK compliance) before submission, or restrict claims to biomarker-discovery with explicit "future clinical-utility studies needed" framing and route to biomarker-discovery venue.

Check whether your Annals of Oncology biomarker claim has clinical utility →

Check whether your Annals of Oncology manuscript is submission-ready →

Use these nearby guides when the target journal is still uncertain:

• Annals Of Oncology journal guide

• Nature Nanotechnology Submission Guide

• Psychological Review Submission Guide

• Nature Reviews Neuroscience Submission Guide

• Nature Reviews Genetics Submission Guide

• Neuroscience and Biobehavioral Reviews Submission Guide

• Cancer Letters Submission Guide

• Cellular and Molecular Life Sciences Submission Guide

• Nature Biotechnology Submission Guide

• JCI Insight Submission Guide

• Molecular Psychiatry Submission Guide

• Detailed submission strategies: Journal Cover Letter Template: 5 Filled-In Examples for Any Journal (2026) provides specific templates for clinical trial and biomarker studies.

• Journal selection guidance: How to Choose the Right Journal for Your Paper (A Practical Guide) compares Annals of Oncology with Lancet Oncology, JAMA Oncology, and other high-impact alternatives.

• Pre-submission assessment: 10 Signs Your Paper Isn't Ready to Submit (Yet) helps identify common weaknesses before you invest time in submission formatting.

Need expert feedback on your Annals of Oncology submission? Manusights provides detailed pre-submission reviews from oncology specialists who understand exactly what ESMO's editors prioritize.

For the related journal overview, see Annals Of Oncology journal guide. In our work on Annals Of Oncology submissions, we observe that editors specifically screen the abstract, first figures, cover letter, and evidence package for whether the manuscript answers the journal's stated fit test; our analysis of Annals Of Oncology pages treats those checks as submission-risk signals, not as official guidance.